Drug Price Trends for NDC 47781-0155

Average Pharmacy Cost for 47781-0155

Drug Name	NDC	Price/Unit ($)	Unit	Date
No data available in table

Best Wholesale Price for NDC 47781-0155

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
NAPROXEN NA 750MG TAB,SA	TWi Pharmaceuticals USA, Inc.	47781-0155-30	30	302.53	10.08433	2023-11-01 - 2028-01-31	FSS
NAPROXEN NA 750MG TAB,SA	TWi Pharmaceuticals USA, Inc.	47781-0155-30	30	302.53	10.08433	2024-01-01 - 2028-01-31	FSS

Market Analysis and Price Projections for NDC 47781-0155: Buprenorphine and Naloxone

The pharmaceutical industry is constantly evolving, with drug prices and market dynamics playing crucial roles in shaping healthcare accessibility and affordability. In this comprehensive analysis, we'll delve into the market outlook and price projections for the drug with National Drug Code (NDC) 47781-0155, which contains buprenorphine and naloxone.

Understanding NDC 47781-0155

NDC 47781-0155 is a combination drug containing buprenorphine and naloxone, packaged by Alvogen Inc[1]. This medication falls under the DEA Schedule CIII category and is classified as a human prescription drug[1]. Buprenorphine and naloxone combination drugs are primarily used in the treatment of opioid dependence.

Current Market Status

The drug market is experiencing significant changes, with various factors influencing pricing and availability. As of 2024, the pharmaceutical industry is projected to see an overall drug price inflation rate of 3.81% for 2025[2]. This projection takes into account expanding indications for previously approved medications and the introduction of high-cost cell and gene therapies.

Factors Influencing Drug Pricing

Several key factors are likely to impact the pricing of NDC 47781-0155:

1. Generic Competition

The presence of generic alternatives significantly affects drug pricing. Generic drugs typically lead to substantial price reductions:

Prices continue to decline by 70% to 80% relative to the pre-generic entry price in markets of 10 or more competitors following 3 years after generic entry[4].

2. Regulatory Changes

The FDA's proposed rule to update the length and format of NDCs from 10 digits to 12 digits could impact drug identification and pricing systems[6]. This change aims to minimize confusion and medication errors while providing certainty in planning for pharmaceutical companies.

3. Industry Trends

The pharmaceutical industry is witnessing several trends that could influence pricing:

• Portfolio diversification based on scientific breakthroughs
• Accelerated R&D through AI and data-driven approaches
• Supply chain optimization for sustainability and resilience[7]

Price Projections for NDC 47781-0155

While specific price projections for NDC 47781-0155 are not available in the provided search results, we can make informed estimates based on industry trends and similar drugs:

Short-term Outlook (1-2 years)

Given the overall drug price inflation rate of 3.81% projected for 2025[2], we might expect a modest increase in the price of NDC 47781-0155 in the short term. However, this could be offset by increased competition in the market for buprenorphine and naloxone combination drugs.

Medium-term Outlook (3-5 years)

As generic competition typically leads to significant price reductions over time, we might anticipate a substantial decrease in the price of NDC 47781-0155 if multiple generic alternatives enter the market. Based on historical data, prices could potentially decline by 70-80% relative to the pre-generic entry price if 10 or more competitors enter the market within 3 years[4].

Long-term Outlook (5+ years)

The long-term pricing of NDC 47781-0155 will likely depend on factors such as:

• The number of generic competitors in the market
• Potential new indications or formulations
• Changes in opioid dependence treatment guidelines
• Healthcare policy reforms

Market Dynamics Affecting NDC 47781-0155

Several market dynamics are likely to influence the demand and pricing of NDC 47781-0155:

1. Opioid Crisis Impact

The ongoing opioid crisis in many countries, particularly the United States, may continue to drive demand for medications used in opioid dependence treatment, potentially affecting the pricing of NDC 47781-0155.

2. Healthcare Policy Changes

Changes in healthcare policies, such as expanded coverage for substance abuse treatment or modifications to prescription drug benefits, could impact the accessibility and pricing of buprenorphine and naloxone combination drugs.

3. Technological Advancements

Innovations in drug delivery systems or the development of new treatments for opioid dependence could influence the market position and pricing of existing medications like NDC 47781-0155.

Strategies for Stakeholders

Various stakeholders in the pharmaceutical industry can adopt strategies to navigate the evolving market for NDC 47781-0155:

For Manufacturers

1. Invest in research and development to improve drug formulations or explore new indications.
2. Optimize supply chains to reduce costs and improve resilience[7].
3. Leverage data and AI to accelerate R&D processes and reduce development costs[7].

For Healthcare Providers

1. Stay informed about generic alternatives and their availability.
2. Consider cost-effective treatment options while maintaining quality care.
3. Advocate for policies that improve drug affordability and accessibility.

For Payers

1. Negotiate pricing agreements with manufacturers based on market trends and generic availability.
2. Implement formulary strategies that balance cost-effectiveness with patient needs.
3. Collaborate with providers to promote appropriate use of opioid dependence treatments.

Future Outlook for NDC 47781-0155

The future of NDC 47781-0155 in the pharmaceutical market will likely be shaped by several factors:

1. Generic Competition

As more generic versions of buprenorphine and naloxone combination drugs enter the market, we can expect increased price competition. This could lead to significant cost savings for patients and healthcare systems.

2. Regulatory Environment

Changes in drug approval processes, pricing regulations, or opioid-related policies could impact the market for NDC 47781-0155 and similar medications.

3. Technological Innovations

Advancements in drug delivery systems or the development of new treatments for opioid dependence could affect the demand for existing medications like NDC 47781-0155.

4. Global Market Expansion

The potential expansion of markets for opioid dependence treatments in developing countries could influence global pricing and availability of NDC 47781-0155.

Implications for Healthcare Costs

The pricing trends of NDC 47781-0155 have significant implications for healthcare costs:

1. Patient Affordability

As generic competition increases, patients may benefit from lower out-of-pocket costs for buprenorphine and naloxone combination drugs.

2. Insurance Coverage

Changes in drug pricing could influence insurance coverage decisions and formulary placements for opioid dependence treatments.

3. Healthcare System Expenditures

Reduced drug costs could lead to overall savings for healthcare systems, potentially allowing for reallocation of resources to other areas of care.

Challenges in Price Forecasting

While market analysis can provide valuable insights, several challenges exist in accurately forecasting drug prices:

1. Market Volatility

The pharmaceutical market is subject to rapid changes due to factors such as regulatory decisions, scientific breakthroughs, and global events.

2. Data Limitations

Access to comprehensive, up-to-date pricing data for specific NDCs can be limited, making precise forecasting challenging.

3. Complex Pricing Mechanisms

Pharmaceutical pricing involves complex negotiations between manufacturers, payers, and pharmacy benefit managers, which can be difficult to predict.

Key Takeaways

• NDC 47781-0155 is a buprenorphine and naloxone combination drug used in opioid dependence treatment.
• The overall drug price inflation rate is projected to be 3.81% for 2025, but generic competition could lead to significant price reductions for specific drugs.
• Market dynamics, including the opioid crisis, healthcare policy changes, and technological advancements, will influence the pricing and demand for NDC 47781-0155.
• Stakeholders should adopt strategies to navigate the evolving market, such as investing in R&D, optimizing supply chains, and leveraging data and AI.
• The future outlook for NDC 47781-0155 will be shaped by generic competition, regulatory changes, technological innovations, and global market expansion.
• Accurate price forecasting remains challenging due to market volatility, data limitations, and complex pricing mechanisms.

FAQs

1. Q: What is the current price of NDC 47781-0155? A: The current price of NDC 47781-0155 is not provided in the given search results. Prices can vary depending on factors such as location, pharmacy, and insurance coverage.

2. Q: How does generic competition affect drug prices? A: Generic competition typically leads to significant price reductions. Studies show that prices can decline by 70-80% relative to the pre-generic entry price in markets with 10 or more competitors after 3 years.

3. Q: What factors influence pharmaceutical pricing? A: Factors influencing pharmaceutical pricing include generic competition, regulatory changes, industry trends, technological advancements, and market dynamics such as the opioid crisis and healthcare policy changes.

4. Q: How might the proposed NDC format change impact drug pricing? A: The FDA's proposed rule to update NDCs from 10 digits to 12 digits aims to minimize confusion and medication errors. While not directly impacting pricing, it could affect drug identification and pricing systems used by healthcare providers and payers.

5. Q: What strategies can healthcare providers adopt to manage costs related to NDC 47781-0155? A: Healthcare providers can stay informed about generic alternatives, consider cost-effective treatment options while maintaining quality care, and advocate for policies that improve drug affordability and accessibility.

Sources cited: [1] https://www.pharmacompass.com/ndc-47781-357-11 [2] https://www.vizientinc.com/newsroom/news-releases/2024/vizient-projects-drug-price-inflation [4] https://aspe.hhs.gov/sites/default/files/documents/510e964dc7b7f00763a7f8a1dbc5ae7b/aspe-ib-generic-drugs-competition.pdf [6] https://www.fda.gov/media/184345/download?attachment [7] https://www.zs.com/insights/pharmaceutical-trends-2025-outlook-ai-supplychain-and-beyond